Enterprise Value
-17.57M
Cash
32.17M
Avg Qtr Burn
-6.494M
Short % of Float
0.28%
Insider Ownership
3.23%
Institutional Own.
10.23%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Annamycin Details Soft tissue sarcoma, Solid tumor/s, Cancer, Lung Metastases, Sarcoma | Phase 1/2 Data readout | |
Annamycin + Ara-C Details Blood cancer, Cancer, Acute myeloid leukemia | Phase 1/2 Data readout | |
WP1066 (p-STAT3 inhibitor) Details Brain tumor, Solid tumor/s, Cancer, Glioblastoma | Phase 1/2 Initiation | |
WP1066 (p-STAT3 inhibitor) Details Cancer, Brain tumor, Solid tumor/s, Glioma | Phase 1 Data readout | |
WP1220 Details Cutaneous T cell lymphoma, Blood cancer, Cancer, T-cell lymphoma | Failed Discontinued | |
WP1122 Details COVID-19 | Failed Discontinued |